We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Plant Health Care Plc | LSE:PHC | London | Ordinary Share | GB00B01JC540 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.12 | 3.46% | 3.59 | 3.30 | 3.86 | 3.62 | 3.44 | 3.56 | 675,665 | 16:35:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pesticides, Agric Chems, Nec | 11.77M | -9.48M | -0.0278 | -1.30 | 12.36M |
Date | Subject | Author | Discuss |
---|---|---|---|
27/2/2024 14:02 | So 2023 profits were stolen by 2022 over-purchase by distributors. Look forward to getting the 2023 TS out of the way. We all know it’s going to be poor. As soon as the destocking issue resolves we can get back on track. I regret the lost year, but we live in unpredictable times. | pretax2 | |
27/2/2024 09:15 | More comments on destocking in the crop protection market this morning from Croda i Quote Crop Protection is developing sustainable crop care solutions as well as delivery systems for biopesticides, launching two new delivery systems, one specially designed for biologicals and the second for drone delivery. Following an exceptional 2022, when Crop Protection delivered both strong double-digit percentage volume growth and price/mix, the business started the year with good momentum, but began to experience rapid customer destocking in the second quarter. Volume weakness continued throughout the second half year, to fall 21% year-on-year with a small offset from positive price/mix, resulting in sales falling 19% overall. In Seed Enhancement, most sales are derived from providing just-in-time enhancement services for vegetable seeds so the business only saw a limited impact from destocking, delivering 9% sales growth driven by strong structural growth trends. Seed Enhancement is winning market share through its leadership in microplastic-free seed coatings which are in high demand following the EU's decision to ban the use of microplastics in agriculture in the next five years | cerrito | |
22/2/2024 07:47 | One way to deal with destocking is to give distributors a new product to stock. Like Saori in Mexico. Well done PHC | pretax2 | |
20/2/2024 08:45 | While I am unsure about the read across between PHC and FMC, I note that in their February 5th results outlook statement FMC referred to continued destocking in the US crop protection market in H1 with some recovery in H2. | cerrito | |
20/2/2024 07:28 | Unfortunatly we know how reliable they are | kaos3 | |
20/2/2024 07:15 | A TU documenting the impact of unprecedented de-stocking. I’m not looking forward to that one. The forward statement is more important. Most pundits suggest that the de-stocking issue will be resolved by H2. Will be glad to see the back of it. | pretax2 | |
17/2/2024 18:12 | I note that since January 23rd when Spreadex finished raising their stake,trading volumes have been low.On the basis that the annual results come out early May, I am going on the basis we will shortly get a TU updating us on events since November 22nd. | cerrito | |
13/1/2024 20:20 | Thank you. Doesn't mean they won't come back to the market, but it looks like they won't do so unless they are left with no alternative. | mjneish | |
09/1/2024 20:42 | Concerning fundrasing I asked JT just before Xmas, his response below. ------------- ME: Do you still hold the view that no more capital raises are necessary by the company before profits? To do so at the current share-price would be terrible for stockholders. JT: We would prefer not to go back to the market since it would indeed be terrible for shareholders. If additional capital is needed, we are considering several options that will help us get to cash breakeven. ------------- Possibilities might include a bridging loan or issuing sustainable bonds perhaps? The current destocking situation is likely to persist for H1 2024 but new registrations (e.g. Sugar Cane in India) provide the opportunity for PHC to grow their way into profitability. Elsewhere the Brazil PHC field team are going gangbusters promoting Teikko. If they were footballers, they're be in the premier league. Profits can't be too far away now and they have some juicy tax breaks to look forward to once they arrive. | pretax2 | |
09/1/2024 18:03 | Just given them a quick look and have a question about their cash position. They had about $5.7 million in cash at the end of June after having raised $3.6 million in May. This could be rather less by the end of year, so it's looking a bit tight. Given that they are moving to just above break-even this year (Cavendish's figures) if there is no slippage, what's the likelihood of a further fundraising this year? Thanks. | mjneish | |
02/1/2024 08:46 | Agreed. Fortunately the PHC field team in Brazil (who are excellent) have been doing a considerable amount of pre-approval promotion of Teikko; mentioning it at conferences, journal papers and promotional events. Given that Teikko gives equivalent or better results to conventional approaches, I imagine relative product cost will be a powerful motivator for growers. Other advantages - tank-mix compatibility and shelf life are important. I tend to think that there’s and appetite for Teikko in Brazil. The article on PHC949 in Agropages was the second most read article in Agropages last year. More importantly, with $215m to go at, there’s huge scope for growth with this product, and that’s just in Brazil soy. | pretax2 | |
02/1/2024 07:44 | Good news. I note the timing of the approval is spot on with what they said in the interims but much sooner than the 1 to 2 years referred to in their May 9 2023 RNS when they announced it had jumped the first hurdle. No idea why they are not automatically using the Saori distributor. Be interesting to see how much in revenues they get in this upcoming soy harvest season and the brokers ' forecast. From the top of my head and with all the advantage of ignorance, I would say USd 1m, given how conservative farmers are. I wonder how many farmers like to brag about their ESG credentials, although good that the RNS mentioned the other advantages. Given start up costs it may not wash its face profit or cash wise this season. | cerrito | |
21/12/2023 21:49 | all strange and un usual going on for ... lets say last 12 months Griffith starts selling they do not know what to do ... took a look ... maybe sell, maybe this or that start saying about how good it will all be, so much revenue, new products , boasting ... like a liar who without being asked starts appologizing and explaining the issue something is going on behind the curtains if i remember an old bod member went away etc smells all this and each item listed can be rationally explained , i know it all, so do not bother | kaos3 | |
21/12/2023 20:58 | Thanks pretax2 for sharing that. I am even more confused. Yes good that they are reviewing all eventualities but the way this is worded suggests that they have little confidence of the (albeit v small) cash flow surplus forecast for 2024 of the broker. | cerrito | |
21/12/2023 17:58 | JT comment in reply to email 6/12 “We would prefer not to go back to the market since it would indeed be terrible for shareholders. If additional capital is needed, we are considering several options that will help us get to cash breakeven.” I note ‘if’ additional capital need and continuing confidence about reaching breakeven in the foreseeable future. | pretax2 | |
21/12/2023 09:24 | Broker comment "Strong recovery likely in 2024. Looking ahead, with a proven and growing product portfolio showing resilience in a tough market, we continue to see Plant Health Care as significantly undervalued and likely to recover strongly in 2024" | callumross | |
21/12/2023 07:53 | I see that the broker has put out a note and sees closing net cash at the end of this year as £4.8m and end 2024 at £5.1m(down from £4.9m and £6.2m after the interims), reiterating a target price of 42p. It also notes the issuance of options at a strike price of 1p for 0.51pc of the share capital. Fair enough but I still think in terms of PR they have shot themselves in the foot. The only occasion I have had when because of a need to conserve cash directors have deferred cash remuneration was with a pre revenue Biotech SAR about 8 years ago when their liquidity issues were both real and well flagged. Have you folks had any such instances? While it makes sense for a NED, who as I understand it is associated with RG, to leave there is only one truly independent NED and would be good to get another in. | cerrito | |
20/12/2023 08:14 | They stated that the commercial business was consistently EBITDA positive and cash generative.Inventori | geraldus | |
20/12/2023 08:04 | I found the RNS this morning spooky. Did not appreciate that the liquidity situation was so bad that the executive directors have had to reduce their cash remuneration received over the next year. | cerrito | |
19/12/2023 21:01 | There has been little trading of the shares so far this month so RG is being patient. At the end of June he had 10.81% so at this rate he will be out in six months time. I note that in April 2019 he had 36%. Perhaps the Board/Cenkos smelt at mid year that his selling would depress the price and so got the funding at that time. I see the other day he increased his holding in Cirata ex Wandisco | cerrito | |
19/12/2023 16:00 | Griffith still selling. Is he going all the way? 5% left to go. Can’t last forever. Suspect Griffith is the only reason we’re getting smashed. Sooner he’s done the better. | pretax2 | |
18/12/2023 17:32 | Not sure if the closing share price is the lowest ever or just for a v v long time, but there seems to have been very little trading today. | cerrito | |
27/11/2023 07:48 | Let’s see how reliable a morning star reversal is. | pretax2 | |
24/11/2023 09:24 | Spooky, I’m no trader; in for the long term. I agree the story hasn’t changed. PHC experiencing the downstream impact of covid 19. Their products are sustainable, work and are selling globally. Most of the research and regulatory admin costs are behind us and we are still showing small growth despite unprecedented levels of destocking across the industry. | pretax2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions